Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS.

Author: ArmendarizA M, Cano-DominguezC, FernandezH, Garcia-CosioC, KershenovichJ, Orozco-TopeteR, Ortiz-PedrozaG, Romo-GarciaJ, RozhonE J, Sierra-MaderoJ, Soria-CordobaA, Teran-ToledoX, Vazquez-VallsE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study evaluated the safety and effectiveness of Virend (SP-303), a new topical antiviral agent, for treating recurrent genital herpes lesions in patients with AIDS. Virend showed promise in promoting healing and reducing viral cultures.
Paper Details　
Original Abstract of the Article :
Virend (SP-303), a new topical antiviral agent with activity against herpesvirus, was evaluated in a multicenter, double-blind, placebo-controlled Phase II study for safety and effectiveness against recurrent genital herpes lesions in patients with AIDS. The primary endpoints of this study were comp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0166-3542(97)00015-6

データ提供：米国国立医学図書館（NLM）

Safety and Efficacy of Virend for Genital and Anal Herpes Simplex Lesions

Herpes simplex virus (HSV) infections, like persistent desert mirages, can reappear even after treatment. This study investigates the safety and effectiveness of Virend, a topical antiviral agent, for treating recurrent genital and anal herpes lesions in patients with AIDS. The researchers conducted a multicenter, double-blind, placebo-controlled trial, with 24 patients receiving Virend and 21 receiving placebo. They found that Virend was associated with complete healing of lesions in a significantly higher number of patients compared to placebo, indicating its potential as a treatment option for HSV infections in this population.

Virend for Herpes Simplex Treatment

This study suggests that Virend can be a promising treatment option for recurrent genital and anal herpes lesions in patients with AIDS. It's like using a special desert balm to soothe and heal the sores caused by persistent mirages. This study provides valuable evidence for the potential of Virend as a topical antiviral agent for HSV infections in this population.

Managing Herpes Infections Effectively

Herpes simplex infections are a common concern for many individuals, particularly those with compromised immune systems. It's like navigating a desert landscape where mirages can easily mislead and cause trouble. Finding effective and safe treatments is crucial for managing HSV infections and improving quality of life.

Dr. Camel's Conclusion

This study offers a glimmer of hope for individuals with AIDS struggling with recurrent herpes simplex lesions. It's like finding a helpful guide in the desert of HSV infections, offering a potential path to healing and relief. Further research is necessary to fully understand the long-term effectiveness and safety of Virend, but the initial findings are promising, paving the way for future investigations into this topical antiviral agent.
Date :
  1. Date Completed 1997-09-25
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

9217246

DOI: Digital Object Identifier

10.1016/s0166-3542(97)00015-6

Related Literature

Article Analysis
・Effective treatment of genital herpes
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.